April 7, 2021 7:58pm

While the downside shares pricing’s drops led the session to yet another deeper low

Pre-open indication results: 7 HIT and 3 Miss

The sector is what it is, until it isn’t and even then, it doesn’t seem to be …

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors

Where are the canaries in the sector coal mine, am I the only one? 

The Dow closed UP +16.02 points (+0.05%); the S&P closed UP +6.01 points (+0.15%) while the Nasdaq closed DOWN -9.54 points (-0.07%)

 

Henry’omics:

Indexes were weak and mixed on Wednesday, with the S&P 500 hovering near its record high as investors awaited details from the Fed’s last policy meeting.

Fed officials indicated in their last meeting that the pace of asset purchases will stay the same for some time while the central bank pursues its economic goals.

  • “Participants noted that it would likely be some time until substantial further progress toward the Committee’s maximum-employment and price-stability goals would be realized and that, consistent with the Committee’s outcome-based guidance, asset purchases would continue at least at the current pace until then,” the meeting minutes read.
  • The minutes also said, “Real GDP growth was projected to be substantial this year and the unemployment rate was forecast to decline markedly.”

 

RegMed Investors’ (RMi) pre-open: “RegMed Investors’ (RMi) pre-open: share pricing exhibits a streaking on the field anticipating a tackling. Streaking is an act or instance of running naked, usually for a short distance.” …  https://www.regmedinvestors.com/articles/11853

 

Pre-open indication results:  7 HITs <Maintain SELL: Biostage (BSTG -$0.00 to $1.25 with 967): SELL into Offering: Homology Medicine FIXX -$2.12 - offering), Ionis Pharmaceuticals (IONS -$3.60 - private placement), Editas Medicine (EDIT -$2.24), Intellia Therapeutics (NTLA -$8.53), Sangamo Therapeutics (SGMO -$0.61); SELL into Strength: Vericel (VCEL -$0.07) and 3 MISS <CRISPR Therapeutics (CRSP -$3.10), Fate Therapeutics (FATE -$4.40), Voyager Therapeutics (VYGR -$0.14)>

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Wednesday opened negative at 8/25, 1 flat and 1 acquired, stayed negative at the mid-day to 7/26, 1 flat and 1 acquired, closing negative at 3/30, 1 flat and 1 acquired;

 

There are clear winners and losers

Jumping with share pricing momentum: yesterday’s dogs get to bark again

  • Solid Biosciences (SLDB), Mesoblast (MESO) to name 3 of the 3 inclining of the 35 covered

Hammered in today’s market:

  • Intellia Therapeutics (NTLA), ReNeuron (RENE.L), Fate Therapeutics (FATE), Ultragenyx (RARE), Ionis Pharmaceuticals (IONS) to name 5 of the 30 declining of the 35 covered

 

Key metrics:

  • Sector volume had LOW with 0 of the 3-upside having higher than the 3-month average volume with the volume of 4 of 30-downside having higher than the 3-month average volume;
  • Wednesday’s percentage (%) of the 3-upside were +0.12% (MESO) to +5.35% (SLDB) while the 30-downside ranges from -0.13% (VCEL) to -22.80% (FIXX);

 

Wednesday’s (3 of 3) incline

  • Solid Biosciences (SLDB +$0.28);
  • Pluristem (PSTI +$0.10);
  • Mesoblast (MESO +$0.01 after Tuesday’s +$0.19 and Monday’s -$0.05);

Wednesday’s (10 of 30) decliners:

  • Intellia Therapeutics (-$8.53 after Tuesday’s -$0.61);
  • ReNeuron (RENE.L -$5.00 after Tuesday’s +$1.50);
  • Fate Therapeutics (FATE -$4.40 after Tuesday’s -$3.56 after Monday’s -$1.75);
  • Ultragenyx (RARE -$3.92 after Tuesday’s -$4.23);
  • Ionis Pharmaceuticals (IONS -$3.60 after Tuesday’s +$0.41 and Monday’s +$1.79);
  • CRISPR Therapeutics (CRSP -$3.10);
  • Editas Medicine (EDIT -$2.24);
  • Homology Medicine (FIXX -$2.12 after Tuesday’s -$0.33)
  • BioLife Solutions (BLFS -$1.95 after Tuesday’s +$1.09 and Monday’s -$0.97);
  • Alnylam Pharmaceuticals (ALNY -$1.34 after Tuesday’s -$0.64 and Monday’s +$0.84):

Closing: 1 – Biostage (BSTG) and 1 - Stemline Therapeutics (STML – acquired)

 

Sentiment and COVID-19:

  • The post-vaccination signs have left some health experts puzzled and looking to science for answers. Some had trouble getting out of bed months after Covid-19 diagnosis. It wasn’t until about five days after the first Pfizer shot in February that many began to feel better <including me>.

Infection cases <Million>: never to forget …

  • Wednesday vaccinations: 171 M
  • Wednesday 30.662 M cases,
  • Wednesday’s death rate totaled 555,231 <Johns Hopkins University>

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB closed down -1.79% and XBI closed down -2.41%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -0.96 points or -5.30% at 17.16

Upside volume: low

  • Wednesday: 0 out of the 3-upside had higher than the 3-month average volume;

Downside volume: low

  • Wednesday: 4 out of the 30-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Wednesday’s percentage (%) of the 3-upside were +0.12% (MESO) to +5.35% (SLDB) while the 30-downside ranges from -0.13% (VCEL) to -22.80% (FIXX);

 

April, the beginning of Q2/21:

Wednesday closed negative with 3 advancers, 30 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: After Monday’s “streak”, Tuesday “dump to the scrapheap” and Wednesday’s diving … there are lots of reasons to be excited about the months ahead, and I am optimistic about the near-term; however, the short-term momentum blasts give me ‘the itches”!

Sector momentum remains “sketchy” and these alternative session breathers seems to guarantee more uncertainty and risks.

NEWS, clinical – non-financial (i.e., raising capital) need to flow!!!

Investors are here to make money from investments that is WHY, I say SELL into Strength!

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

Don’t get complacent …

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.